Anticorps Polyclonal de lapin anti-FRS2

• Phare
• Validé par KD/KO

FRS2 Polyclonal Antibody for WB, IF, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris et plus (1)

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

Publications

10

N° de cat : 11503-1-AP

Synonymes

FGFR signaling adaptor SNT, FGFR substrate 2, FRS2, FRS2A, FRS2alpha, SNT, SNT 1, SNT1

---

Galerie de données de validation

• 

  WB analysis using 11503-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 11503-1-AP (FRS2 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of SH-SY5Y using 11503-1-AP

  WB result of FRS2 antibody (11503-1-AP; 1:600; incubated at room temperature for 1.5 hours) with sh-Control and sh-FRS2 transfected SH-SY5Y cells.

• 

  WB analysis of NIH/3T3 using 11503-1-AP

  NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 11503-1-AP (FRS2 Antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human brain using 11503-1-AP

  human brain tissue were subjected to SDS PAGE followed by western blot with 11503-1-AP (FRS2 antibody) at dilution of 1:400 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human prostate cancer using 11503-1-AP

  Immunohistochemical analysis of paraffin-embedded human prostate cancer using 11503-1-AP (FRS2 antibody) at dilution of 1:50 (under 10x lens).

• 

  IF Staining of MCF-7 using 11503-1-AP

  Immunofluorescent analysis of MCF-7 cells using 11503-1-AP (FRS2 antibody) at dilution of 1:25 and Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Applications testées

• Résultats positifs en WB: cellules HeLa, cellules NIH/3T3, cellules PC-3, cellules SH-SY5Y, tissu cérébral humain
• Résultats positifs en IHC: tissu de cancer de la prostate humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules MCF-7

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:4000
• Immunohistochimie (IHC): IHC : 1:20-1:200
• Immunofluorescence (IF)/ICC: IF/ICC : 1:10-1:100

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 9 publications below
• IHC: See 2 publications below

Informations sur le produit

11503-1-AP cible FRS2 dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: Humain, singe, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: FRS2 Protéine recombinante Ag2052
• Nom complet: fibroblast growth factor receptor substrate 2
• Masse moléculaire calculée: 60 kDa
• Poids moléculaire observé: 68 kDa
• Numéro d’acquisition GenBank: BC021562
• Symbole du gène: FRS2
• Identification du gène (NCBI): 10818
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Fibroblast growth factor (FGF) receptor substrate 2 (FRS2) has an alternative name as SNT-1, it is an adapter protein that links activated FGR and NGF receptors to downstream signaling pathways. FGF receptor substrates (FRS2 and FRS3) are key adaptor proteins that mediate FGF-FGFR signalling in benign as well as malignant tissue. FRS2 is a 508 amino-acid protein,which is phosphorylated on tyrosine residues. The molecular weight of non-phosphorylated FRS2 is 57-68 kDa, but phosphorylated FRS2 is 80-90 kDa. Phosphorylation of FRS2 is associated with activation of a number of MAP kinases. Allele-specific regulation of FGFR2 mRNA expression with a mildly increased breast cancer risk has been reported.

Publications

Species	Application	Title
	WB	Cancer Res; Transcriptomics and transposon mutagenesis identify multiple mechanisms of resistance to the FGFR inhibitor AZD4547.; Authors - Sjors M Kas
human	IHC	Cancer Res; Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.; Authors - Zhang Keqiang K
mouse	WB	J Med Chem; Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.; Authors - Min Shao
mouse	WB	Cells; FGF9, a Potent Mitogen, Is a New Ligand for Integrin αvβ3, and the FGF9 Mutant Defective in Integrin Binding Acts as an Antagonist; Authors - Chih-Chieh Chang
human	WB	Breast Cancer Res; FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.; Authors - Silvana Mouron
human	WB	Genes Chromosomes Cancer; High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.; Authors - Wang Xiaoke X

Produits associés

GRB2 Polyclonal antibody

10254-2-AP

FGFR1 Monoclonal antibody

60325-1-Ig

PTPN11/SHP2 Polyclonal antibody

20145-1-AP

ERK1/2 Polyclonal antibody

16443-1-AP

NUDT6 Polyclonal antibody

11181-1-AP

SOS1 Polyclonal antibody

55041-1-AP